T1	PROC 45 73	Estudio abierto de extensión
T2	PROC 79 113	valorar la seguridad y efectividad
T3	PROC 118 129	tratamiento
#1	AnnotatorNotes T3	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T4	DISO 163 182	enfermedad de Crohn
#2	AnnotatorNotes T4	C0010346; Crohn Disease; Disease or Syndrome
T5	PROC 237 295	ESTUDIO ABIERTO DE EXTENSIÓN Y SUPERVISIÓN DE LA SEGURIDAD
T6	DISO 313 332	ENFERMEDAD DE CROHN
#3	AnnotatorNotes T6	C0010346; Crohn Disease; Disease or Syndrome
T7	PROC 395 416	PROTOCOLO DE FASE III
T8	DISO 474 508	enfermedad inflamatoria intestinal
#4	AnnotatorNotes T8	C0021390; Inflammatory Bowel Diseases; Disease or Syndrome
T9	DISO 533 552	Enfermedad de Crohn
#5	AnnotatorNotes T9	C0010346; Crohn Disease; Disease or Syndrome
T10	PROC 587 615	Estudio abierto de extensión
T11	PROC 770 798	estudio abierto de extensión
T12	PROC 843 852	protocolo
#6	AnnotatorNotes T12	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T13	CHEM 802 813	etrolizumab
#7	AnnotatorNotes T13	C3177463; etrolizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T14	PROC 1082 1091	protocolo
#8	AnnotatorNotes T14	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T15	PROC 1138 1165	seguimiento de la seguridad
#9	AnnotatorNotes T15	C5235447; Safety Monitoring; Research Activity
T16	PROC 1195 1198	OLE
#10	AnnotatorNotes T16	C1709323; Open Label Study; Research Activity (?)
T17	PROC 1308 1336	Estudio abierto de extensión
T18	DISO 1350 1362	comorbilidad
#11	AnnotatorNotes T18	C1275743; Co-morbid conditions; Finding
T19	ANAT 498 508	intestinal
#12	AnnotatorNotes T19	C0021853; Intestines; Body Part, Organ, or Organ Component | C1318303; Entire intestine; Body Part, Organ, or Organ Component
T20	PROC 617 620	OLE
#13	AnnotatorNotes T20	C1709323; Open Label Study; Research Activity (?)
T21	CHEM 936 947	etrolizumab
#14	AnnotatorNotes T21	C3177463; etrolizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T22	PROC 1069 1072	OLE
#15	AnnotatorNotes T22	C1709323; Open Label Study; Research Activity (?)
T23	CHEM 421 432	ETROLIZUMAB
#16	AnnotatorNotes T23	C3177463; etrolizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T24	CHEM 134 145	etrolizumba
T25	CHEM 686 697	etrolizumab
#17	AnnotatorNotes T25	C3177463; etrolizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T26	Date 13 17	2014
T27	LIVB 149 158	pacientes
#18	AnnotatorNotes T27	C0030705; Patients; Patient or Disabled Group
T28	LIVB 299 308	PACIENTES
#19	AnnotatorNotes T28	C0030705; Patients; Patient or Disabled Group
T29	LIVB 622 631	Pacientes
#20	AnnotatorNotes T29	C0030705; Patients; Patient or Disabled Group
T30	LIVB 892 901	Pacientes
#21	AnnotatorNotes T30	C0030705; Patients; Patient or Disabled Group
T33	LIVB 1027 1036	Pacientes
#22	AnnotatorNotes T33	C0030705; Patients; Patient or Disabled Group
T34	LIVB 1102 1111	pacientes
#23	AnnotatorNotes T34	C0030705; Patients; Patient or Disabled Group
T35	Duration 1169 1179	12 semanas
T31	PROC 1408 1432	Supervisión de Seguridad
#24	AnnotatorNotes T31	C0150370; Surveillance: safety; Therapeutic or Preventive Procedure
T32	PROC 862 886	Supervisión de Seguridad
#25	AnnotatorNotes T32	C0150370; Surveillance: safety; Therapeutic or Preventive Procedure
A1	Status T25 History_of
A2	Status T11 History_of
A3	Status T13 History_of
A4	Status T21 History_of
A5	Status T22 History_of
A6	Status T15 History_of
A7	Status T16 History_of
#26	AnnotatorNotes T24	C3177463; etrolizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
#27	AnnotatorNotes T7	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure + C0282461; Phase 3 Clinical Trials; Research Activity
T36	Neg_cue 971 973	no
T37	Observation 1001 1011	participar
A8	Assertion T37 Negated
#28	AnnotatorNotes T37	C1278516; Patient participation status; Finding
T38	Neg_cue 998 1000	no
T39	Observation 978 983	aptos
A9	Assertion T39 Negated
#29	AnnotatorNotes T39	C1302261; Patient eligible for clinical trial; Finding (?)
T40	Observation 906 932	participaron en el estudio
#30	AnnotatorNotes T40	C2242969; clinical trial participant (history); Finding
T41	Neg_cue 1386 1388	no
T42	Quantifier_or_Qualifier 1389 1399	controlada
A10	Assertion T42 Negated
T43	Neg_cue 1436 1438	No
T44	CONC 1443 1465	criterios de exclusión
A11	Assertion T44 Negated
#31	AnnotatorNotes T44	C0680251; Exclusion Criteria; Functional Concept
T45	Observation 721 761	cumplieron los criterios de eligibilidad
#32	AnnotatorNotes T45	C1302261; Patient eligible for clinical trial; Finding (?)
T46	Quantifier_or_Qualifier 200 216	moderada a grave
#33	AnnotatorNotes T46	C1299393; Moderate to severe; Qualitative Concept
R1	Has_Quantifier_or_Qualifier Arg1:T4 Arg2:T46	
T47	Quantifier_or_Qualifier 350 366	MODERADA A GRAVE
R2	Has_Quantifier_or_Qualifier Arg1:T6 Arg2:T47	
#34	AnnotatorNotes T47	C1299393; Moderate to severe; Qualitative Concept
R3	Experiences Arg1:T27 Arg2:T3	
R4	Used_for Arg1:T24 Arg2:T3	
R5	Experiences Arg1:T27 Arg2:T4	
R6	Experiences Arg1:T28 Arg2:T6	
R7	Experiences Arg1:T28 Arg2:T23	
R8	Location_of Arg1:T19 Arg2:T8	
#35	AnnotatorNotes T10	C1709323; Open Label Study; Research Activity (?)
#36	AnnotatorNotes T11	C1709323; Open Label Study; Research Activity (?)
#37	AnnotatorNotes T17	C1709323; Open Label Study; Research Activity (?)
T48	Observation 367 388	PREVIAMENTE INSCRITOS
#38	AnnotatorNotes T48	C4684790; Study Subject Enrolled; Finding
A12	Status T48 History_of
T49	Observation 648 668	estuvieron inscritos
A13	Status T49 History_of
#39	AnnotatorNotes T49	C4684790; Study Subject Enrolled; Finding
R9	Experiences Arg1:T29 Arg2:T25	
R10	Overlap Arg1:T49 Arg2:T25	
R11	Experiences Arg1:T29 Arg2:T13	
R12	Experiences Arg1:T30 Arg2:T21	
R13	Negation Arg1:T36 Arg2:T39	
R14	Has_Quantifier_or_Qualifier Arg1:T30 Arg2:T39	
R15	Negation Arg1:T38 Arg2:T37	
T50	Observation 1041 1053	participaron
A14	Status T40 History_of
A15	Status T50 History_of
#40	AnnotatorNotes T50	C2242969; clinical trial participant (history); Finding
R16	Has_Duration_or_Interval Arg1:T15 Arg2:T35	
T51	Observation 1124 1165	completado el seguimiento de la seguridad
#41	AnnotatorNotes T51	C5554829; Follow-Up Completed; Finding (?)
T52	Observation 1243 1253	participar
R17	Before Arg1:T51 Arg2:T52	
#42	AnnotatorNotes T52	C1278516; Patient participation status; Finding
R18	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T42	
R19	Negation Arg1:T41 Arg2:T42	
T53	Quantifier_or_Qualifier 1370 1383	significativa
#43	AnnotatorNotes T53	C1546944; Event Seriousness - Significant; Qualitative Concept
R20	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T53	
R21	Negation Arg1:T43 Arg2:T44	
T54	Quantifier_or_Qualifier 1363 1368	nueva
#44	AnnotatorNotes T54	C0205314; New; Qualitative Concept
R22	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T54	
#45	AnnotatorNotes T2	C0511730; Identify product efficacy and safety issues; Health Care Activity
#46	AnnotatorNotes T1	C1709323; Open Label Study; Research Activity (?)
A16	Experiencer T27 Patient
A17	Experiencer T28 Patient
A18	Experiencer T29 Patient
A19	Experiencer T30 Patient
A20	Experiencer T33 Patient
A21	Experiencer T34 Patient
